Report Detail
Global (United States, European Union and China) Tumor Necrosis Factor Alpha Inhibitors Market Research Report 2019-2025
- RnM3641281 |
- 02 August, 2019 |
- Global |
- 113 Pages |
- QYResearch |
- Pharma & Healthcare
The tumor necrosis factor alpha (TNF-a) inhibitors represent one of the major treatment methods for inflammatory diseases. Globally, this drug class is known to be the most successful drugs in the overall pharmaceutical industry. Several conditions such as inflammations, rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and seronegative spondyloarthropathies, can be treated with the help of these drugs.
In 2019, the market size of Tumor Necrosis Factor Alpha Inhibitors is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Tumor Necrosis Factor Alpha Inhibitors.
This report studies the global market size of Tumor Necrosis Factor Alpha Inhibitors, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Tumor Necrosis Factor Alpha Inhibitors sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
GlaxoSmithKline
Sanofi
Novartis
AstraZeneca
AbbVie
LG Life Sciences
Janssen Biotech
AryoGen Pharmed
Momenta Pharmaceuticals
HanAll Biopharma
Zydus Cadila
Market Segment by Product Type
Humira
Enbrel
Remicade
Others
Market Segment by Application
Medicine
Scientific Research
Others
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Tumor Necrosis Factor Alpha Inhibitors status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Tumor Necrosis Factor Alpha Inhibitors manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Tumor Necrosis Factor Alpha Inhibitors are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Tumor Necrosis Factor Alpha Inhibitors Market Size Growth Rate by Type (2019-2025)
- 1.3.2 Humira
- 1.3.3 Enbrel
- 1.3.4 Remicade
- 1.3.5 Others
- 1.4 Market Segment by Application
- 1.4.1 Global Tumor Necrosis Factor Alpha Inhibitors Market Share by Application (2019-2025)
- 1.4.2 Medicine
- 1.4.3 Scientific Research
- 1.4.4 Others
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Tumor Necrosis Factor Alpha Inhibitors Market Size
- 2.1.1 Global Tumor Necrosis Factor Alpha Inhibitors Revenue 2014-2025
- 2.1.2 Global Tumor Necrosis Factor Alpha Inhibitors Sales 2014-2025
- 2.2 Tumor Necrosis Factor Alpha Inhibitors Growth Rate by Regions
- 2.2.1 Global Tumor Necrosis Factor Alpha Inhibitors Sales by Regions 2014-2019
- 2.2.2 Global Tumor Necrosis Factor Alpha Inhibitors Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Tumor Necrosis Factor Alpha Inhibitors Sales by Manufacturers
- 3.1.1 Tumor Necrosis Factor Alpha Inhibitors Sales by Manufacturers 2014-2019
- 3.1.2 Tumor Necrosis Factor Alpha Inhibitors Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Tumor Necrosis Factor Alpha Inhibitors Revenue by Manufacturers (2014-2019)
- 3.2.2 Tumor Necrosis Factor Alpha Inhibitors Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Tumor Necrosis Factor Alpha Inhibitors Market Concentration Ratio (CR5 and HHI)
- 3.3 Tumor Necrosis Factor Alpha Inhibitors Price by Manufacturers
- 3.4 Key Manufacturers Tumor Necrosis Factor Alpha Inhibitors Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Tumor Necrosis Factor Alpha Inhibitors Market
- 3.6 Key Manufacturers Tumor Necrosis Factor Alpha Inhibitors Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 Humira Sales and Revenue (2014-2019)
- 4.1.2 Enbrel Sales and Revenue (2014-2019)
- 4.1.3 Remicade Sales and Revenue (2014-2019)
- 4.1.4 Others Sales and Revenue (2014-2019)
- 4.2 Global Tumor Necrosis Factor Alpha Inhibitors Sales Market Share by Type
- 4.3 Global Tumor Necrosis Factor Alpha Inhibitors Revenue Market Share by Type
- 4.4 Tumor Necrosis Factor Alpha Inhibitors Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Tumor Necrosis Factor Alpha Inhibitors Sales by Application
6 United States
- 6.1 United States Tumor Necrosis Factor Alpha Inhibitors Breakdown Data by Company
- 6.2 United States Tumor Necrosis Factor Alpha Inhibitors Breakdown Data by Type
- 6.3 United States Tumor Necrosis Factor Alpha Inhibitors Breakdown Data by Application
7 European Union
- 7.1 European Union Tumor Necrosis Factor Alpha Inhibitors Breakdown Data by Company
- 7.2 European Union Tumor Necrosis Factor Alpha Inhibitors Breakdown Data by Type
- 7.3 European Union Tumor Necrosis Factor Alpha Inhibitors Breakdown Data by Application
8 China
- 8.1 China Tumor Necrosis Factor Alpha Inhibitors Breakdown Data by Company
- 8.2 China Tumor Necrosis Factor Alpha Inhibitors Breakdown Data by Type
- 8.3 China Tumor Necrosis Factor Alpha Inhibitors Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Tumor Necrosis Factor Alpha Inhibitors Breakdown Data by Company
- 9.2 Rest of World Tumor Necrosis Factor Alpha Inhibitors Breakdown Data by Type
- 9.3 Rest of World Tumor Necrosis Factor Alpha Inhibitors Breakdown Data by Application
- 9.4 Rest of World Tumor Necrosis Factor Alpha Inhibitors Breakdown Data by Countries
- 9.4.1 Rest of World Tumor Necrosis Factor Alpha Inhibitors Sales by Countries
- 9.4.2 Rest of World Tumor Necrosis Factor Alpha Inhibitors Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 GlaxoSmithKline
- 10.1.1 GlaxoSmithKline Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Tumor Necrosis Factor Alpha Inhibitors
- 10.1.4 Tumor Necrosis Factor Alpha Inhibitors Product Introduction
- 10.1.5 GlaxoSmithKline Recent Development
- 10.2 Sanofi
- 10.2.1 Sanofi Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Tumor Necrosis Factor Alpha Inhibitors
- 10.2.4 Tumor Necrosis Factor Alpha Inhibitors Product Introduction
- 10.2.5 Sanofi Recent Development
- 10.3 Novartis
- 10.3.1 Novartis Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Tumor Necrosis Factor Alpha Inhibitors
- 10.3.4 Tumor Necrosis Factor Alpha Inhibitors Product Introduction
- 10.3.5 Novartis Recent Development
- 10.4 AstraZeneca
- 10.4.1 AstraZeneca Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Tumor Necrosis Factor Alpha Inhibitors
- 10.4.4 Tumor Necrosis Factor Alpha Inhibitors Product Introduction
- 10.4.5 AstraZeneca Recent Development
- 10.5 AbbVie
- 10.5.1 AbbVie Company Details
- 10.5.2 Company Description and Business Overview
- 10.5.3 Sales, Revenue and Market Share of Tumor Necrosis Factor Alpha Inhibitors
- 10.5.4 Tumor Necrosis Factor Alpha Inhibitors Product Introduction
- 10.5.5 AbbVie Recent Development
- 10.6 LG Life Sciences
- 10.6.1 LG Life Sciences Company Details
- 10.6.2 Company Description and Business Overview
- 10.6.3 Sales, Revenue and Market Share of Tumor Necrosis Factor Alpha Inhibitors
- 10.6.4 Tumor Necrosis Factor Alpha Inhibitors Product Introduction
- 10.6.5 LG Life Sciences Recent Development
- 10.7 Janssen Biotech
- 10.7.1 Janssen Biotech Company Details
- 10.7.2 Company Description and Business Overview
- 10.7.3 Sales, Revenue and Market Share of Tumor Necrosis Factor Alpha Inhibitors
- 10.7.4 Tumor Necrosis Factor Alpha Inhibitors Product Introduction
- 10.7.5 Janssen Biotech Recent Development
- 10.8 AryoGen Pharmed
- 10.8.1 AryoGen Pharmed Company Details
- 10.8.2 Company Description and Business Overview
- 10.8.3 Sales, Revenue and Market Share of Tumor Necrosis Factor Alpha Inhibitors
- 10.8.4 Tumor Necrosis Factor Alpha Inhibitors Product Introduction
- 10.8.5 AryoGen Pharmed Recent Development
- 10.9 Momenta Pharmaceuticals
- 10.9.1 Momenta Pharmaceuticals Company Details
- 10.9.2 Company Description and Business Overview
- 10.9.3 Sales, Revenue and Market Share of Tumor Necrosis Factor Alpha Inhibitors
- 10.9.4 Tumor Necrosis Factor Alpha Inhibitors Product Introduction
- 10.9.5 Momenta Pharmaceuticals Recent Development
- 10.10 HanAll Biopharma
- 10.10.1 HanAll Biopharma Company Details
- 10.10.2 Company Description and Business Overview
- 10.10.3 Sales, Revenue and Market Share of Tumor Necrosis Factor Alpha Inhibitors
- 10.10.4 Tumor Necrosis Factor Alpha Inhibitors Product Introduction
- 10.10.5 HanAll Biopharma Recent Development
- 10.11 Zydus Cadila
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Tumor Necrosis Factor Alpha Inhibitors Sales Channels
- 11.2.2 Tumor Necrosis Factor Alpha Inhibitors Distributors
- 11.3 Tumor Necrosis Factor Alpha Inhibitors Customers
12 Market Forecast
- 12.1 Global Tumor Necrosis Factor Alpha Inhibitors Sales and Revenue Forecast 2019-2025
- 12.2 Global Tumor Necrosis Factor Alpha Inhibitors Sales Forecast by Type
- 12.3 Global Tumor Necrosis Factor Alpha Inhibitors Sales Forecast by Application
- 12.4 Tumor Necrosis Factor Alpha Inhibitors Forecast by Regions
- 12.4.1 Global Tumor Necrosis Factor Alpha Inhibitors Sales Forecast by Regions 2019-2025
- 12.4.2 Global Tumor Necrosis Factor Alpha Inhibitors Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Tumor Necrosis Factor Alpha Inhibitors. Industry analysis & Market Report on Tumor Necrosis Factor Alpha Inhibitors is a syndicated market report, published as Global (United States, European Union and China) Tumor Necrosis Factor Alpha Inhibitors Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Tumor Necrosis Factor Alpha Inhibitors market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
